Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine RIGVIR® is looking for partners globally to support and finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
We have elaborated collaboration model for Rigvir combination with chekpoint inhibitors and registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the followin:
Clinical studies from 1968
First genetically non-modified virus
One of the fastest growing biotech companies of the Northern Europe
Proven in clinical practice for more than 10 years